NRx Pharmaceuticals (NRXP) has repaid the remaining $5.4M balance sheet debt to Anson Funds through equity conversion of common stock. There were no warrants or other repricing mechanisms associated with this transaction. Anson originally lent $16.2M to the Company to fund repayment of prior loans and corporate operating expenses. With this repayment, the Company anticipates ending the 2025 calendar year with a balance sheet free of all debt.
Claim 50% Off TipRanks Premium and Invest with Confidence
- Unlock hedge-fund level data and powerful investing tools designed to help you make smarter, sharper decisions
- Stay ahead of the market with the latest news and analysis so your portfolio is always positioned for maximum potential
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on NRXP:
- Vanguard Total Stock Market ETF (VTI) Daily Update—12/17/25
- Vanguard Total Stock Market ETF (VTI) Daily Update—12/16/25
- NRx Pharmaceuticals’ KETAFREE ANDA Acceptance: A Milestone for Market Position and Revenue Growth
- Vanguard Total Stock Market ETF (VTI) Daily Update—12/15/25
- Vanguard Total Stock Market ETF (VTI) Daily Update—12/12/25